PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 2,500
- 主要终点
- Creation of a cohort of psoriasis subjects
研究概览
简要总结
This is a 24-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 16 (+/- 5 days) and 24 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 16 and Week 24) using a structured and standardized data collection tool.
详细描述
Data collected through the study may be used to address a range of research questions and use cases and objectives, including but not limited to study
- Creation of a cohort of psoriasis subjects to describe the clinical and patient-reported outcomes (PRO) and changes at 16 and 24 weeks after initiation of the advanced therapy.
- Inform clinical decision making by subjects and treating providers. This will be enabled through the standardized data collection including validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the recording of medication utilization data.
- Describe subject characteristics (i.e. comorbidity, medication history, sociodemographic) at baseline.
- For subjects with a dermatologist-confirmed diagnosis of psoriatic arthritis at baseline, to describe the joint pain and patient wellness.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •To be eligible to participate in this study, an individual must meet all the following criteria:
- •Patient is at least 18 years of age at the time of study enrollment.
- •Patient has a diagnosis of moderate to severe plaque psoriasis based on an investigator Global Assessment (IGA, score of 3 or 4 at the time of Enrollment).
- •Patient is initiating new Eligible Medication for the first time for the treatment of PSO.
- •Patient is willing and able to provide informed consent to participate in this study.
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in the study:
- •Patient is participating in a blinded clinical trial.
- •Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study.
- •Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study.
- •B. Patients otherwise meeting eligibility criteria can be enrolled in the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study C. Following completion or at time of Exit from the PPDTM CorEvitasTM Psoriasis (PSO) Early Treatment Response Non-Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow-up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.
结局指标
主要结局
Creation of a cohort of psoriasis subjects
时间窗: Baseline (Day 0), Week 16 and 24 weeks after initiation of advanced therapy
Creation of a cohort of psoriasis subjects to describe the changes at 16 and 24 weeks after initiation of advanced therapy. The changes will be determined by completion of questionnaires
次要结局
未报告次要终点